These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [On delimitation of the concepts of "renal osteodystrophy" and "renal rickets"]. De Toni G Minerva Pediatr; 1972 Jul; 24(26):1061-6. PubMed ID: 5069819 [No Abstract] [Full Text] [Related]
23. Renal osteodystrophy in Ramathibodi Hospital: histomorphometry and clinical correlation. Changsirikulchai S; Domrongkitchaiporn S; Sirikulchayanonta V; Ongphiphadhanakul B; Kunkitti N; Stitchantrakul W; Radienahamed P J Med Assoc Thai; 2000 Oct; 83(10):1223-32. PubMed ID: 11143489 [TBL] [Abstract][Full Text] [Related]
24. [A pathological analysis of 51 cases of renal osteodystrophy]. Yu YF; Hu YX; Zhu P Zhonghua Nei Ke Za Zhi; 1993 Jul; 32(7):448-50. PubMed ID: 8275821 [TBL] [Abstract][Full Text] [Related]
25. [Mineral and bone disturbances associated with chronic kidney disease]. Suchowierska E; Myśliwiec M Pol Merkur Lekarski; 2010 Feb; 28(164):138-43. PubMed ID: 20369744 [TBL] [Abstract][Full Text] [Related]
26. Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease. Lundquist AL; Nigwekar SU Curr Opin Nephrol Hypertens; 2016 Mar; 25(2):120-6. PubMed ID: 26785065 [TBL] [Abstract][Full Text] [Related]
27. Improving global outcomes in mineral and bone disorders. Moe SM; Drüeke T Clin J Am Soc Nephrol; 2008 Nov; 3 Suppl 3(Suppl 3):S127-30. PubMed ID: 18988697 [TBL] [Abstract][Full Text] [Related]
28. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. Sabbagh Y; Graciolli FG; O'Brien S; Tang W; dos Reis LM; Ryan S; Phillips L; Boulanger J; Song W; Bracken C; Liu S; Ledbetter S; Dechow P; Canziani ME; Carvalho AB; Jorgetti V; Moyses RM; Schiavi SC J Bone Miner Res; 2012 Aug; 27(8):1757-72. PubMed ID: 22492547 [TBL] [Abstract][Full Text] [Related]
29. Subtotal parathyroidectomy in azotemic renal osteodystrophy. ANDERSON WW; MANN JB; KENYON N; FARRELL JJ; HILLS AG N Engl J Med; 1963 Mar; 268():575-80. PubMed ID: 14012926 [No Abstract] [Full Text] [Related]
33. Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease. Sugatani T; Agapova OA; Fang Y; Berman AG; Wallace JM; Malluche HH; Faugere MC; Smith W; Sung V; Hruska KA Kidney Int; 2017 Jan; 91(1):86-95. PubMed ID: 27666759 [TBL] [Abstract][Full Text] [Related]
34. Role of bone biopsy in renal osteodystrophy. Al Badr W; Martin KJ Saudi J Kidney Dis Transpl; 2009 Jan; 20(1):12-9. PubMed ID: 19112214 [TBL] [Abstract][Full Text] [Related]
35. Mineral and bone disorders in chronic kidney disease: new insights into mechanism and management. Lewis R Ann Clin Biochem; 2012 Sep; 49(Pt 5):432-40. PubMed ID: 22807503 [TBL] [Abstract][Full Text] [Related]
36. Changing bone patterns with progression of chronic kidney disease. Drüeke TB; Massy ZA Kidney Int; 2016 Feb; 89(2):289-302. PubMed ID: 26806832 [TBL] [Abstract][Full Text] [Related]
37. [Bone and Nutrition. Nutrition care of renal osteodystrophy]. Tanaka S; Ito M Clin Calcium; 2015 Jul; 25(7):1057-62. PubMed ID: 26119320 [TBL] [Abstract][Full Text] [Related]
38. [Diagnosis and classification of renal osteodystrophy]. Yajima A; Ogawa Y Clin Calcium; 2004 May; 14(5):727-30. PubMed ID: 15577033 [TBL] [Abstract][Full Text] [Related]
39. A brief history in nephrology pharmacotherapy. Quan DJ Nephrol Nurs J; 2009; 36(2):223-7. PubMed ID: 19397179 [TBL] [Abstract][Full Text] [Related]
40. Renal osteodystrophy: alpha-Heremans Schmid glycoprotein/fetuin-A, matrix GLA protein serum levels, and bone histomorphometry. Coen G; Ballanti P; Balducci A; Grandi F; Manni M; Mantella D; Pierantozzi A; Ruggeri M; Sardella D; Sorbo G; Bonucci E Am J Kidney Dis; 2006 Jul; 48(1):106-13. PubMed ID: 16797392 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]